{
    "2021-10-29": [
        [
            {
                "time": "",
                "original_text": "企业观 | 全面布局细胞及基因治疗，高瓴减持凯莱英加大投注新技术领域CXO公司 减持股份",
                "features": {
                    "keywords": [
                        "高瓴",
                        "减持",
                        "凯莱英",
                        "细胞及基因治疗",
                        "CXO"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "干货！2021年中国医药制造外包(CMO)行业龙头企业发展分析——药明康德：CMO行业的“侵略者”",
                "features": {
                    "keywords": [
                        "药明康德",
                        "CMO",
                        "龙头",
                        "医药制造外包"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "外包服务"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "领跑CDMO赛道却遭高瓴减持 凯莱英赴港二次上市有何玄机？",
                "features": {
                    "keywords": [
                        "凯莱英",
                        "CDMO",
                        "高瓴",
                        "减持",
                        "赴港上市"
                    ],
                    "sentiment_score": -0.4,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "中信建投医药大健康团队最新研究",
                "features": {
                    "keywords": [
                        "中信建投",
                        "医药",
                        "大健康",
                        "研究"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "大健康"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}